Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 927 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: AdverseEvent Clear all
Completed No phase listed Observational

Testing a Spanish Version of a Patient Toxicity Questionnaire

NCT01517152
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Lung Cancer, Lymphoma, Myeloma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 23, 2026, 6:27 PM EDT
Terminated Phase 2 Interventional Results available

Digoxin In Treatment of Alcohol Associated Hepatitis

NCT05014087
View directory record Official record
Conditions
Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury, Alcohol-Induced Disorders, Steatohepatitis Caused by Ingestible Alcohol
Interventions
Intravenous digoxin
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Completed Phase 2 Interventional

Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

NCT00006345
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lymphoma
Interventions
denileukin diftitox, dexamethasone
Biological · Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
11
States / cities
Miami, Florida • Chicago, Illinois • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 23, 2026, 6:27 PM EDT
Recruiting No phase listed Observational

Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy

NCT05158894
View directory record Official record
Conditions
Migraine
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 23, 2026, 6:27 PM EDT
Active, not recruiting Phase 1 Interventional

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

NCT05753501
View directory record Official record
Conditions
Hematologic Cancer
Interventions
ABBV-101, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
14
States / cities
Tucson, Arizona • Orange, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Completed Phase 4 Interventional Results available

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

NCT04908475
View directory record Official record
Conditions
Psoriasis
Interventions
Risankizumab, Apremilast
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
26
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 23, 2026, 6:27 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Observation of Outcomes and Side Effects of Cesium-131 in Combination With External Beam Radiation for the Treatment of Intermediate to High Risk Prostate Cancer

NCT00621413
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
IsoRay Medical, Inc.
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
9
States / cities
Phoenix, Arizona • Rancho Mirage, California • San Mateo, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 23, 2026, 6:27 PM EDT
Completed Phase 3 Interventional Results available

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer

NCT00245050
View directory record Official record
Conditions
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
pyridoxine hydrochloride, Placebo, doxorubicin HCL liposome
Dietary Supplement · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
8
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 30, 2011 · Synced Oct 23, 2026, 6:27 PM EDT
Recruiting Not applicable Interventional

Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial

NCT04419480
View directory record Official record
Conditions
Cardiogenic Shock, Heart Failure, Ambulatory Hemodynamic Monitoring
Interventions
CardioMEMS implantation with routine ambulatory pulmonary artery pressure monitoring and medication optimization
Device
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)

NCT06977724
View directory record Official record
Conditions
Dry Eye Syndrome, Systemic Lupus Erythematosus
Interventions
ABBV-319
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Avon Park, Florida • Clearwater, Florida • Margate, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Completed No phase listed Observational

Prostate Cancer Survey

NCT03128710
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Male only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 23, 2026, 6:27 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

NCT05512390
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma
Interventions
ABBV-319
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Tucson, Arizona • Miami, Florida • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Completed Not applicable Interventional

Design & Evaluation of a Medication Therapy Management Program to Improve Patient Safety in Medicare Beneficiaries

NCT00773942
View directory record Official record
Conditions
Chronic Illness, Adverse Effects, Medication Errors, Elderly Patients
Interventions
Basic medication therapy management, Enhanced medication therapy management
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
65 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Chicago, Illinois • Durham, North Carolina • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 23, 2026, 6:27 PM EDT
Suspended Early Phase 1 Interventional

Sodium Thiosulfate Otoprotection During Salvage Cisplatin Therapy

NCT05756660
View directory record Official record
Conditions
Ototoxicity, Drug-Induced
Interventions
Sodium Thiosulfate
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Month to 39 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Recruiting Not applicable Interventional

The Geriatric Emergency Department Pharmacologic Harm Prevention Project

NCT07216846
View directory record Official record
Conditions
Fall, Fall Accident, Poly Pharmacy, Adverse Drug Events, Pharmacogenomic Drug Interaction, Pharmacogenomic Testing
Interventions
DNA care pathway
Other
Lead sponsor
Florida Atlantic University
Other
Eligibility
65 Years to 110 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Delray Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The Intraoperative Complication Assessment and Reporting With Universal Standards - Calculator (ICARUS-C)

NCT05270603
View directory record Official record
Conditions
Intraoperative Complications, Surgery--Complications, Surgery, Surgical Procedure, Unspecified
Interventions
ICARUS intraoperative adverse events calculator
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 23, 2026, 6:27 PM EDT
Completed Phase 3 Interventional Results available

Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

NCT00460746
View directory record Official record
Conditions
HIV
Interventions
TMC125, Darunavir; Ritonavir
Drug
Lead sponsor
Tibotec, Inc
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Oct 23, 2026, 6:27 PM EDT
Recruiting Phase 2 Interventional

Investigation to Understand and Optimize Psilocybin

NCT06512194
View directory record Official record
Conditions
Depression
Interventions
Psilocybin, Transcutaneous Auricular Vagus Nerve Stimulation (taVNS), Sham taVNS
Drug · Device
Lead sponsor
Charles Raison
Other
Eligibility
18 Years to 70 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Edwards, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Recruiting Phase 3 Interventional

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

NCT06810505
View directory record Official record
Conditions
Chronic Migraine
Interventions
Atogepant, Placebo for Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 17 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
32
States / cities
Huntsville, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Completed No phase listed Observational Results available

Methadone Monitoring for Insights Into Adverse Events

NCT01191242
View directory record Official record
Conditions
Pain, Opiate Addiction
Interventions
Not listed
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Murray, Utah • Taylorsville, Utah
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 23, 2026, 6:27 PM EDT
Terminated Phase 2 Interventional

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

NCT06844669
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2+ Breast Cancer
Interventions
Carvedilol, Empagliflozin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

NCT06953960
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Surzetoclax, Daratumumab, Dexamethasone, Pomalidomide, Etentamig
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
12
States / cities
Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 6:27 PM EDT
Terminated Phase 2Phase 3 Interventional

Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

NCT04857359
View directory record Official record
Conditions
Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Interventions
Dipraglurant, Placebo
Drug
Lead sponsor
Addex Pharma S.A.
Industry
Eligibility
30 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
41
States / cities
Phoenix, Arizona • Fresno, California • Irvine, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 23, 2026, 6:27 PM EDT
Completed No phase listed Observational

Cardiovascular Effects of CART Cell Therapy

NCT04026737
View directory record Official record
Conditions
Leukemia, Lymphoma, Cardiotoxicity, Risk Factor, Cardiovascular, Immunotherapy
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 23, 2026, 6:27 PM EDT